Syndax Pharmaceuticals, Inc.
SNDX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $24 | $0 | $0 | $140 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $1 | $0 | $0 | $0 |
| Gross Profit | $23 | $0 | $0 | $140 |
| % Margin | 96.5% | – | – | 100% |
| R&D Expenses | $242 | $163 | $118 | $88 |
| G&A Expenses | $121 | $67 | $33 | $25 |
| SG&A Expenses | $121 | $67 | $33 | $25 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $363 | $230 | $152 | $113 |
| Operating Income | -$340 | -$230 | -$152 | $26 |
| % Margin | -1,434.4% | – | – | 18.8% |
| Other Income/Exp. Net | $21 | $21 | $2 | -$1 |
| Pre-Tax Income | -$319 | -$209 | -$149 | $25 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$319 | -$209 | -$149 | $25 |
| % Margin | -1,346.1% | – | – | 17.8% |
| EPS | -3.73 | -2.98 | -2.46 | 0.48 |
| % Growth | -25.2% | -21.1% | -612.5% | – |
| EPS Diluted | -3.73 | -2.98 | -2.46 | 0.48 |
| Weighted Avg Shares Out | 86 | 70 | 61 | 52 |
| Weighted Avg Shares Out Dil | 86 | 70 | 61 | 52 |
| Supplemental Information | – | – | – | – |
| Interest Income | $26 | $21 | $6 | $0 |
| Interest Expense | $5 | $0 | $3 | $2 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$314 | -$209 | -$146 | $27 |
| % Margin | -1,325.3% | – | – | 19.2% |